US district court favours Pharmacyclics against Natco on Imbruvica
In 2018 NATCO and Alvogen had filed an Abbreviated New Drug Application (ANDA) with PIV certification for the generic version of the product
In 2018 NATCO and Alvogen had filed an Abbreviated New Drug Application (ANDA) with PIV certification for the generic version of the product
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
Subscribe To Our Newsletter & Stay Updated